6NQ.F BIOMED-LUBLIN WYT.SUR.

Healthcare Biotechnology Frankfurt Exchange
0.5660 EUR
Close of Nov 11, 2026
0.5660 0.9980
Market cap
EUR 43.0M
P/E
-
P/B
1.64x
ROE
-10.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6NQ.F undervalued?

Graham number

The Graham number of BIOMED-LUBLIN WYT.SUR. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOMED-LUBLIN WYT.SUR. fundamental analysis

No fundamental analysis for BIOMED-LUBLIN WYT.SUR. yet.

BIOMED-LUBLIN WYT.SUR. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOMED-LUBLIN WYT.SUR.

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladde…

Full company profile